DMSG - Deutsche Multiple Sklerose Gesellschaft Bundesverband e.V.

Immunmodulatorische Stufentherapie der Multiplen Sklerose

Literaturliste Immunmodulatorische Stufentherapie der Multiplen Sklerose

  1. ACHIRON A, ROTSTEIN Z, NOY S, MASHIACH S, DULITZKY M, ACHIRON R (1996) Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 243: 25–28
  2. ACHIRON A, GABBAY U, GILAD R, HASSIN-BAER S, BARAK Y, GORNISH M, et al (1998) Intravenous immunoglobulin treatment in multiple sclerosis-Effect on relapses. Neurology 50: 398–402.
  3. ALAM J, MCALLISTER A, SCARAMUCCI J, JONES W, ROGGE M (1997) Pharmacokinetics and pharmacodynamics of interferon beta-1a in healthy volunteers after intravenous, subcutaneous or intramuscular administration. Clin. Drug Invest 14: 35–43.
  4. ANDERSSON PB, GOODKIN DE (1998) Glucocorticosteroid therapy for multiple sclerosis: a critical review. J. Neurol. Sci. 18: 16–25.
  5. ARNASON BGW, REDER AT (1994) Interferons and multiple sclerosis. Clin Neuropharmocol 6: 495–547.
  6. ARNASON BGW, DIANZANI F (1998) Correlation of the appearance of anti-interferon antibodies during treatment and diminution of efficacy: Summary of an international workshop on anti-interferon antibodies. J. Interferon Cytokine Res 18: 639–644.
  7. BARNES D, HUGHES RAC, MORRIS RW, WADE-JONES O, BROWN P, BRITTON T, et al (1997) Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349: 902–906.
  8. BASTIANELLO S, POZZILLI C, D’ANDREA F, MILLEFIORINI E, TROJANO M, MORINO S, et al (1994) A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 21: 266–270.
  9. BECK RW, CLEARY PA, ANDERSON MM, KELTNER JL, SHULTS WT, KAUFMAN DI, et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326: 581–588.
  10. BECK RW (1995) The optic neuritis treatment trial: three-year follow-up results [letter]. Arch Ophthalmol 113: 136–137.
  11. BORNSTEIN MB, MILLER A, SLAGLE S, WEITZMAN M, CRYSTAL H, DREXLER E, et al (1987) A pilot trial of Cop I in exacerbating-remitting multiple sclerosis. N Engl J Med 317: 408–414.
  12. BORNSTEIN MB, MILLER A, SLAGLE S, et al. (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of COP 1 in chronic progressive multiple sclerosis. Neurology 41: 533–539.
  13. BOUMPAS DT( (1993) Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119: 1198–1208.
  14. BRÜCK W, BITSCH A, KOLENDA H, BRÜCK Y, STIEFEL M, LASSMANN H (1997) Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 42: 783–793.
  15. BUTTGEREIT F, WEHLING M, BURMESTER GR (1998) A new hypothesis of modular glucocorticoid actions. Arthritis Rheumat 41: 761–767.
  16. CAVAZZUTI M, MERELLI E, TASSONE G, MAVILLA L (1997) Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment – A retrospective study. Eur Neurol 38: 283–290.
  17. CAZZATO G, MESIANO T, ANTONELLO R, MONTI F, CARRARO N, TORRE P, et al (1995) Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur Neurol 35: 193–198.
  18. COMPSTON A (1996) Remyelination of the central nervous system. Mult Scler 1: 388–392.
  19. CONFAVREUX C, SADDIER P, GRIMAUD J, MOREAU T, ADELEINE P, AIMARD G (1996) Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study. Neurology 46: 1607–1612.
  20. CONFAVREUX C, HUTCHINSON M, HOURS MM, CORTINOVIS-TOURNIAIRE P, MOREAU T (1998) Rate of pregnancy-related relapse in multiple sclerosis. N Eng J Med 339: 283–291.
  21. CROSS AH, ANTEL JP (1998) Antibodies to beta-interferons in multiple sclerosis. Neurology 50: 1206–1208.
  22. DALAKAS MC (1997) Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 126: 721–730.
  23. DAYTON JS, TURKA LA, THOMPSON CB, MITCHEL BS (1991) Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferationand purine ribonecleotide metabolism. Mol Pharmacol 41: 671–676.
  24. EDAN G, MILLER D, CLANET M, CONFAVREUX C, LYON CAEN O, LUBETZKI C, et al (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62: 112–118.
  25. ELION GB (1993) The pharmacology of azathioprine. Ann N Y Acad Sci 685: 401–407.
  26. EUROPEAN STUDY GROUP ON INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MS, KAPPOS L, MILLER D, POLMAN C, POZZILLI C, THOMPSON A (1998) Interferon beta-1b delays progression of disabilityin secondary progressive multiple sclerosis: Results of a european multicentre randomised study. The Lancet 352: 1491–1497.
  27. FAZEKAS F, DEISENHAMMER F, STRASSER-FUCHS S, NAHLER G, MAMOLI B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. The Lancet 349: 589–593.
  28. FIDLER JM, QUINN DE JOY S, SMITH FR, GIBBONS JJ (1986) Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone treated mice. J Neuroimmunol 136: 2747–2754.
  29. FRIDKIS-HARELI M, STROMINGER JL (1998) Promiscuous binding of synthetic Copolymer 1 to purified HLA-DR molecules. J Immunol 160: 4386–4397.
  30. GOLD R, RIECKMANN P (1998) Pathogenese und Therapie der Multiplen Sklerose. Uni-Med Verlag, Bremen.
  31. GONSETTE RE (1996) Mitoxantrone immunotherapy in multiple sclerosis. Multiple Sclerosis 1: 329–332.
  32. GOODKIN DE, BAILLY RC, TEETZEN ML, HERTSGAARD D, BEATTY WW (1991) The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 41: 20–25.
  33. GOODKIN DE, KINKEL RP, WEINSTOCK-GUTTMAN B, et al. (1998) A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 51, 239–245.
  34. GOODKIN DE, RUDICK RA, VANDERBRUG MEDENDORP S, DAUGHTRY MM, SCHWETZ KM, FISCHER J, et al (1995) Low-dose (7,5 mg) oral methotrexare reduces of rate of progression in chronic progressive multiple sclerosis. Annals of Neurology 37: 30–40.
  35. GOODKIN DE, RUDICK RA, MEDENDORP SVB, DAUGHTRY MM, VAN DYKE C (1996) Low-dose oral methotrexate in chronic progressive multiple sclerosis: Analyses of serial MRIs. Neurology 47: 1153–1157.
  36. HARTUNG HP, KIESEIER B (1996) Targets for therapeutic action of interferon-beta in multiple sclerosis. Ann. Neurol 40: 823–825.
  37. HARTUNG HP, GONSETTE R, MIMS-STUDY GROUP (1998) Mitoxantrone in progressive multiple sclerosis (MS): A placebo-controlled, randomized, observer-blind European phase III multicenter study – clinical results. Multiple Sclerosis 4: 325 (Abstract OR 207).
  38. HOHLFELD R, TOYKA KV, BESINGER UA, GERHOLD B, HEININGER K (1985) Myasthenia gravis: reactivation of clinical disease and ofautoimmune factors after discontinuation of long-term azathioprine. Ann. Neurol 17: 238–242.
  39. HOHLFELD R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis – Principles, problems and perspectives. Brain 120: 863–916.
  40. IFNB MULTIPLE SCLEROSIS STUDY GROUP (1993) Interferon-beta 1b is effective in relapsing-remitting multiple sclerosis: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 653–661.
  41. IFNB MULTIPLE SCLEROSIS STUDY GROUP (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45: 1277–1285.
  42. JACOBS LD, COOKFAIR DL, RUDICK RA, HERNDON RM, ET AL. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39: 283–294.
  43. JACOBS L, JOHNSON KP (1994) A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol 51: 1243–1252.
  44. JOHNSON KP, BROOKS BR, COHEN JA, FORD CC, GOLDSTEIN J, LISAK RP, et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group [see comments]. Neurology 45: 1268–1276.
  45. JOHNSON KP, BROOKS BR, COHEN JA, FORD CC, GOLDSTEIN J, LISAK RP, et al (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50: 701–708.
  46. KAISER H, KLEY HH (1992) Kortisontherapie. Stuttgart, New York: Thieme Verlag.
  47. KAPOOR R, MILLER DH, JONES SJ, PLANT GT, BRUSA A, GASS A, et al (1998) Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology 50: 230–237.
  48. KAPPOS L (1990) Immunsuppressive Therapie der multiplen Sklerose mit Cyclosporin A und Azathioprin. Berlin-Heidelberg: Springer-Verlag.
  49. KOEHLER J, BEER K, PETTE M (1998) Mitoxantron-Therapie bei Multipler Sklerose. Akt Neurol 25: 1–3.
  50. KREMECHUTZKY M, BASKERVILLE J, RICE GPA, EBERS GC (1998) Progressive relapsing and relapsing progressive multiple sclerosis: a re-evaluation. Multiple Sclerosis, 4: 372 (Abstract P 2148).
  51. LAUER K (1994) Multiple Sclerosis in the old world: the new old map. In: Multiple Sclerosis in Europe. An Epidemiological Update. Edited by W Firnhaber, K Lauer. Darmstadt: LTV Press. 13–27.
  52. LEPPERT D, WAUBANT E, BÜRK MR, OKSENBERG JR, HAUSER SL (1996) Interferon beta-1b inhibits gelatinase secretion and in vitromigration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis. Annals of Neurology 40: 846–852.
  53. LUCCHINETTI CF, BRÜCK W, RODRIGUEZ M, LASSMANN H (1996) Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 6: 259–274.
  54. MANCARDI GL, SARDANELLI F, PARODI RC, MELANI E, CAPELLO E, INGLESE M, et al (1998) Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 50: 1127–1133.
  55. MILLEFIORINI E, GASPERINI C, POZZILLI C, D’ANDREA F, BASTIANELLO S, TROJANO M, et al (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 23–month clinical and MRI outcome. J Neurol 244: 153–159.
  56. MILLIGAN NM, NEWCOMBE R, COMPSTON DAS (1987) A double-blind trial of high dose methylprednisolone in patients with multiple sclerosis: 1. clinical effects. J Neurol Neurosurg Psych 50: 511–516.
  57. MOREAU T, BLANC S, RICHE G, CONFAVREUX C (1998) ERAZIMUS: Early Azathioprine versus beta-interferon in multiple sclerosis. Multiple Sclerosis 4: 325 (Abstract).
  58. MUNAFO A, TRINCHARD-LUGAN I, NGUYEN TXQ, BURAGLIO M (1998) Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur. J. Neurol. 5: 187–193.
  59. O’RIORDAN JI, THOMPSON AJ, KINGSLEY DPE, MACMANUS DG, KENDALL BE, RUDGE P, et al (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS – A 10-year follow-up. Brain 121: 493–503.
  60. OLIVERI RL, VALENTINO P, RUSSO C, SIBILIA G, AGUGLIA U, BONO F (1998) Randomized trial comparing two different high doses of methylprednisolone in MS. A clinical and MRI study. Neurology 50: 1833–1836.
  61. OWIMS STUDY GROUP (1998) Interferon beta-1a in multiple sclerosis: dose-dependent clinical and MRI efficacy. 123rd Annual Meeting of the American Neurological Association (Abstract) 18–21 October 1998, Montreal, Canada.
  62. PALACE J, ROTHWELL P (1997) New treatments and azathioprine in multiple sclerosis [letter]. The Lancet 350: 261
  63. PATY DW, GOODKIN D, THOMPSON A, RICE G (1996) Guidelines for physicians with patients on IFNbeta-1b: The use of an assay for neutralizing antibodies (NAB). Neurology 47: 863–866.
  64. PETKAU J, WHITE R (1997) Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis. Multiple Sclerosis 3: 402.
  65. PETTE M, HARTUNG HP, TOYKA KV (1994) Cyclophosphamid in der Therapie der chronisch-progredienten Multiplen Sklerose-kritische Analyse der vorliegenden Studien. Nervenarzt 65: 271–274.
  66. POSER CM, PATY DW, SCHEINBERG L, ET AL (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol 13: 327–31.
  67. PRISMS (PREVENTION OF RELAPSES AND DISABILITY BY INTERFERON BETA-1A SUBCUTANEOUSLY IN MULTIPLE SCLEROSIS) STUDY GROUP (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. The Lancet 352: 1498–1504.
  68. REPORT OF THE QUALITY STANDARDS SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY (1994) Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 44: 1537–1540.
  69. RIECKMANN P, HARTUNG H-P, TOYKA K (1996) Immunmodulatorische Therapie der schubförmigen Multiplen Sklerose. Deutsches Ärzteblatt 46: 3022–3027.
  70. RUDICK RA, SIMONIAN NA, ALAM JA, CAMPION M, SCARAMUCCI JO, JONES W, et al (1998) Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50: 1266–1272.
  71. SCHÖTT D, FREITAG P, LIENERT C, ET AL. (1998) Combination therapy of interferon beta with immunosuppressive drugs in relapsing multiple sclerosis: a pilot study. Eur. J. Neurol. 5: S127 (Abstract).
  72. SELLEBJERG F, FREDERIKSEN JL, NIELSEN PM, OLESEN J (1998) Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 51: 529–534.
  73. SMITH DR, BALASHOV KE, HAFLER DA, KHOURY SJ, WEINER HL (1997) Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia. Ann. Neurol. 42: 313–318.
  74. SØRENSEN PS, WANSCHER B, JENSEN CV, SCHREIBER K, BLINKENBERG M, RAVNBORG M, et al (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50: 1273–1281.
  75. SPULER S, HOHLFELD R (1994) Aktuelle Behandlung der Multiplen Sklerose: Mitoxantron. Nervenarzt 65: 136–138.
  76. STANGEL M, HARTUNG HP, MARX P, GOLD R (1997) Side effects of high-dose intravenous immunoglobulins. Clin. Neuropharmacol 20: 383–393.
  77. STORCH MK, PIDDLESDEN S, HALTIA M, IIVANAINEN M, MORGAN P, LASSMANN H (1998) Multiple Sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 43: 463–471.
  78. TEITELBAUM D, MESHORER A, HIRSHFELD T, ARNON R, SELA M (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1: 242–248.
  79. TEITELBAUM D, AHARONI R, ARNON R, SELA M (1988) Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer COP-1. Proc Natl Acad Sci USA, 9723–9728.
  80. TEITELBAUM D, FRIDKIS-HARELI M, ARNON R, SELA M (1996) Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. Journal of Neuroimmunology 64: 209–217.
  81. THE CANADIAN COOPERATIVE MULTIPLE SCLEROSIS STUDY GROUP (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Lancet 337: 441–446.
  82. TRAPP BD, PETERSON J, RANSOHOFF RM, RUDICK R, MORK S, BO L (1998) Axonal transection in the lesions of multiple sclerosis. N Eng J Med 338: 278–285.
  83. WALTHER EU, DANG T, HARTUNG H-P, HOHLFELD R (1997) Formation of neutralizing antibodies in therapy of multiple sclerosis with interferon btea-1b. Practical procedure in suspected therapeutic failure. Nervenarzt 68: 933–939.
  84. WEINER HL, MACKIN GA, ORAV EJ, HAFLER DA, DAWSON DM, LAPIERRE Y, et al (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment group. Neurology 43: 910–918.
  85. WEINSHENKER BG, BAS B, RICE GPA, et al. (1989) The natural history of multiple sclerosis. 2. Predictive value of the early clinical course. Brain 112: 1419–1428.
  86. YUDKIN P, ELLISON GW, GHEZZI A, GOODKIN DE, HUGHES RA, MCPHERSON K, et al (1991) Overview of azathioprine treatment in multiple sclerosis. The Lancet 338: 1051–1055.
  87. ZETTL U, GOLD R, TOYKA KV, HARTUNG HP (1995) Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis (EAN) of the lewis rat. J. Neuropathol. Exp. Neurol 54: 540–547.
Letzte Aktualisierung: 18.03.2021 13:58